State Street Corp Chemomab Therapeutics Ltd. Transaction History

State Street Corp

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 15, 2022	SELL	$2.33 - $4.0 $17,579 - $30,180	-7,545 Reduced 20.85%	28,640 $71,000
Q2 2022 Aug 15, 2022	BUY	$2.58 - $4.88 $2,009 - $3,801	779 Added 2.2%	36,185 $134,000
Q1 2022 May 16, 2022	BUY	$3.53 - $7.2 $9,591 - $19,562	2,717 Added 8.31%	35,406 $171,000
Q4 2021 Feb 14, 2022	BUY	$6.41 - $11.13 $14,005 - $24,319	2,185 Added 7.16%	32,689 $226,000
Q3 2021 Nov 15, 2021	BUY	$11.08 - $19.17 $337,984 - $584,761	30,504 New	30,504 $338,000

2.68M

Ticker CMMB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 11,431,700
Market Cap $18.2M
Description
Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.